INTRODUCTION
Life-threatening infections caused by Aspergillus fumigatus are increasing
in prevalence, particularly in immunocompromised and neutropic
patients.1 However, antifungal therapies are currently limited to a
small number of compounds. For example, toxicity is an issue for
treatments based on amphotericin B, and a high potential for drug–
drug interactions has been reported between azoles and anticancer
agents or immunosuppressants, and causes difficulty in clinical use.2
Thus, a need exists for effective novel antifungal compounds that are
easy to use in clinical practice